263: Biogen's messy board, Laronde's data problem, & the downside of a boom

1

Introduction

00:00 • 2min

2

Biogen's Board of Directors Changes

01:44 • 3min

3

The Relevance of Disclosures of Susan Langer's Connection to Alex Dennar

04:32 • 5min

4

Biogen's PR Department Told Us It Knew About the Relationship Between Alex Dennar and Susan Langer

09:31 • 3min

5

The Reaction to the Biogen Board's Nominating Susan Langer

12:29 • 2min

6

Susan Langer's Connection to Bob Langer in the Biotech World

14:59 • 2min

7

Biogen's Rocky Path Toward Returning to Normalcy

16:39 • 2min

8

Laurent: A Biotech Startup Ruined by Data Integrity Issues

18:43 • 3min

9

The First Outward Recognized Sign of Trouble at Stat

21:29 • 1min

10

Laurent's Response to Red Flags

22:55 • 2min

11

Laurent's Failure to Reproduce Science

24:42 • 2min

12

The Pressure to Live Up to the Hype That Propelled Lorenda Forward

27:07 • 2min

13

The Future of Moderna Pharmaceuticals

29:02 • 2min

14

Laurent's EQRX Data Issue

30:59 • 2min

15

Theranos and the Biotech Industry

32:33 • 2min

16

The Tension Between Moderna and Moderna Therapeutics

34:05 • 2min

17

The Boom in VC Backed Biotech

36:24 • 3min